Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffett's ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Weight Watchers is Novo Nordisk's latest partnersip.

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...